Exelixis (EXEL) Gross Profit (2012 - 2026)
Exelixis (EXEL) recorded quarterly Gross Profit of $590.9 million in Q2 2026, up 3.26% quarter-over-quarter from $572.2 million in Q1 2026, and up 10.18% on a YoY basis from $536.3 million in Q2 2025.
Exelixis (EXEL) Gross Profit (2012 - 2026) Analysis & Trends
Exelixis' Gross Profit history runs 15 years deep, the most recent figure standing at $590.9 million for Q2 2026.
- In Q2 2026, Gross Profit rose 10.18% year-over-year to $590.9 million; the TTM figure through Apr 2026 stood at $2.3 billion (up 2.98% YoY), while the FY2026 annual figure was $2.2 billion, up 6.88% from the prior year.
- Gross Profit was $590.9 million for Q2 2026 at Exelixis, up from $572.2 million in the prior quarter.
- In the past five years, Gross Profit ranged from a high of $619.5 million in Q2 2024 to a low of $342.8 million in Q2 2022.
- Historically, Gross Profit has averaged $484.2 million across 5 years, with a median of $457.9 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Gross Profit jumped 37.02% in 2024, then dropped 11.42% in 2025.
- A 5-year view of Gross Profit shows it stood at $408.0 million in 2022, then climbed by 12.23% to $457.9 million in 2023, then increased by 14.05% to $522.2 million in 2024, then rose by 10.91% to $579.2 million in 2025, then advanced by 2.02% to $590.9 million in 2026.
- The last three Gross Profit figures came in at $590.9 million (Q2 2026), $572.2 million (Q1 2026), and $579.2 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Exelixis | 13.37 Bn | 12.59 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 590.86 Mn |
| Apr 3, 2026 | 590.86 Mn |
| Jan 2, 2026 | 572.18 Mn |
| Jan 2, 2026 | 572.18 Mn |
| Oct 3, 2025 | 579.18 Mn |
| Oct 3, 2025 | 579.18 Mn |
| Jul 4, 2025 | 548.79 Mn |
| Jul 4, 2025 | 548.79 Mn |
| Apr 4, 2025 | 536.28 Mn |
| Apr 4, 2025 | 536.28 Mn |
| Jan 3, 2025 | 546.79 Mn |
| Jan 3, 2025 | 546.79 Mn |
| Sep 27, 2024 | 522.21 Mn |
| Sep 27, 2024 | 522.21 Mn |
| Jun 28, 2024 | 619.51 Mn |
| Jun 28, 2024 | 619.51 Mn |
| Mar 29, 2024 | 403.97 Mn |
| Mar 29, 2024 | 403.97 Mn |
| Dec 29, 2023 | 457.90 Mn |
| Dec 29, 2023 | 457.90 Mn |